Interesting Times Ahead6 Jun 2026 06:08
One thing that stands out to me is how unusual the current situation is compared to Sareum’s historical behaviour.
Historically, Sareum has generally been proactive with fundraising. They have typically raised capital well before cash became critically low, ensuring they always had sufficient runway to progress programmes and avoid finding themselves under pressure.
At 31 December 2025 the company reported £2.49m cash. Since then they have continued normal corporate operations, ongoing business development activities and, importantly, funded the restarted 16-week Phase 2-enabling toxicology programme for SDC-1801, which is now approaching completion.
Even using conservative assumptions, the company has likely consumed a substantial proportion of its cash reserves during the first half of 2026. By now, Sareum is probably operating with one of the lowest cash balances it has carried in recent years without having announced a placing.
That’s the part I find interesting.
If management believed they would ultimately need to fund Phase 2 development alone, history suggests they would likely have raised already. Instead, they appear to have deliberately focused available cash on getting the tox package completed while repeatedly highlighting partnering discussions and business development activities.
A completed Phase 2-enabling package significantly increases the attractiveness of SDC-1801 to potential partners. The timing therefore raises an obvious question: why raise capital today at a modest valuation if management believes a licensing deal, strategic partnership or other value-creating transaction may be achievable once the tox data is in hand?
Nobody outside the company knows what discussions are taking place, but the combination of declining cash reserves, no recent fundraising, completion of a major value inflection point and Sareum’s historically cautious approach to cash management does make the current situation look different from previous years.
If management can deliver positive toxicology results and convert even one of the partnership discussions into a meaningful commercial agreement, the current market value could look remarkably disconnected from the underlying opportunity. The fact they have chosen to push all the way to this catalyst without returning to the market for funding may prove to be one of the most telling signals investors have seen for some time!
Sign In
Follow the stocks
